Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Debt (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Non-Current Debt for 12 consecutive years, with $1.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Non-Current Debt fell 5.93% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Jun 2025, down 5.93%, and an annual FY2024 reading of $1.4 million, down 1.47% over the prior year.
  • Non-Current Debt was $1.3 million for Q2 2025 at China Pharma Holdings, down from $1.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $1.5 million in Q3 2022 and bottomed at $325072.0 in Q2 2021.
  • Average Non-Current Debt over 5 years is $1.3 million, with a median of $1.4 million recorded in 2025.
  • The sharpest move saw Non-Current Debt tumbled 83.56% in 2021, then rose 2.46% in 2024.
  • Year by year, Non-Current Debt stood at $325072.0 in 2021, then skyrocketed by 373.74% to $1.5 million in 2022, then decreased by 8.32% to $1.4 million in 2023, then dropped by 1.47% to $1.4 million in 2024, then dropped by 5.12% to $1.3 million in 2025.
  • Business Quant data shows Non-Current Debt for CPHI at $1.3 million in Q2 2025, $1.4 million in Q1 2025, and $1.4 million in Q4 2024.